Tag: tabirafusp alfa tedromer

Kodiak’s Phase 3 DAYBREAK trial met its primary endpoint for both Zenkuda and KSI-501 in wet AMD. Zenkuda stood out as 54% of patients reached 24-week dosing, while KSI-501 met noninferiority without yet establishing a clear added benefit from IL-6 inhibition.